Cited by 808Venous Thromboembolism Diagnosis and ManagementBlood Coagulation and Thrombosis MechanismsAtrial Fibrillation Management and Outcomes

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism

Open access

Ridker, Paul M, Goldhaber, Samuel Z., Danielson, Ellie, Rosenberg, Yves, Eby, Charles S., Deitcher, Steven R., Cushman, Mary, Moll, Stephan, Kessler, Craig M., Elliott, C. Gregory, Paulson, Rolf, Wong, Turnly, Bauer, Kenneth A., Schwartz, Bruce A., Miletich, Joseph P., Bounameaux, Henri, Glynn, Robert J.·2003·New England Journal of Medicine

DOI 10.1056/nejmoa035029

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Standard therapy to prevent recurrent venous thromboembolism includes 3 to 12 months of treatment with full-dose warfarin with a target international normalized ratio (INR) between 2.0 and 3.0. However, for long-term management, no therapeutic agent has shown an acceptable benefit-to-risk ratio. METHODS: Patients with idiopathic venous thromboembolism who had received full-dose anticoagulation therapy for a median of 6.5 months were randomly assigned to placebo or low-intensity warfarin (target INR, 1.5 to 2.0). Participants were followed for recurrent venous thromboembolism, major hemorrhage, and death. RESULTS: The trial was terminated early after 508 patients had undergone randomization and had been followed for up to 4.3 years (mean, 2.1). Of 253 patients assigned to placebo, 37 had recurrent venous thromboembolism (7.2 per 100 person-years), as compared with 14 of 255 patients assigned to low-intensity warfarin (2.6 per 100 person-years), a risk reduction of 64 percent (hazard ratio, 0.36 [95 percent confidence interval, 0.19 to 0.67]; P<0.001). Risk reductions were similar for all subgroups, including those with and those without inherited thrombophilia. Major hemorrhage occurred in two patients assigned to placebo and five assigned to low-intensity warfarin (P=0.25). Eight patients in the placebo group and four in the group assigned to low-intensity warfarin died (P=0.26). Low-intensity warfarin was thus associated with a 48 percent reduction in the composite end point of recurrent venous thromboembolism, major hemorrhage, or death. According to per-protocol and as-treated analyses, the reduction in the risk of recurrent venous thromboembolism was between 76 and 81 percent. CONCLUSIONS: Long-term, low-intensity warfarin therapy is a highly effective method of preventing recurrent venous thromboembolism.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa035029

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Mutation in blood coagulation factor V associated with resistance to activated protein C
Bertina, R. M., Koeleman, B. P. C., Koster, T., Rosendaal, F. R., Dirven, R. J., de Ronde, H., van der Velden, P. A., & Reitsma, P. H. (1994) · Nature · doi:10.1038/369064a0 · Cited by 3,769
A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis
Poort, S., Rosendaal, F. R., Reitsma, P. H., & Bertina, R. M. (1996) · Blood · doi:10.1182/blood.v88.10.3698.bloodjournal88103698 · Cited by 3,045
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
The Long-Term Clinical Course of Acute Deep Venous Thrombosis
Prandoni, P., Lensing, A. W. A., Cogo, A., Cuppini, S., Villalta, S., Carta, M., Cattelan, A. M., Polistena, P., Bernardi, E., & Prins, M. H. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-1-199607010-00001 · Cited by 2,094
Resistance to Activated Protein C as a Basis for Venous Thrombosis
Svensson, P. J., & Dahlbäck, B. (1994) · New England Journal of Medicine · doi:10.1056/nejm199402243300801 · Cited by 1,127
A Comparison of Three Months of Anticoagulation with Extended Anticoagulation for a First Episode of Idiopathic Venous Thromboembolism
Kearon, C., Gent, M., Hirsh, J., Weitz, J. I., Kovacs, M. J., Anderson, D. R., Turpie, A. G. G., Green, D., Ginsberg, J. S., Wells, P. S., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903253401201 · Cited by 1,057
Mutation in the Gene Coding for Coagulation Factor V and the Risk of Myocardial Infarction, Stroke, and Venous Thrombosis in Apparently Healthy Men
Ridker, P. M., Hennekens, C. H., Lindpaintner, K., Stampfer, M. J., Eisenberg, P. R., & Miletich, J. P. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504063321403 · Cited by 1,031
Self-citation
A Comparison of Six Weeks with Six Months of Oral Anticoagulant Therapy after a First Episode of Venous Thromboembolism
Schulman, S., Rhedin, A.-S., Lindmarker, P., Carlsson, A., Lärfars, G., Nicol, P., Loogna, E., Svensson, E., Ljungberg, B., Walter, H., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506223322501 · Cited by 932
Very Low Doses of Warfarin Can Prevent Thrombosis in Central Venous Catheters
Bern, M. M., Lokich, J. J., Wallach, S. R., Bothe, A., Benotti, P. N., Arkin, C. F., Greco, F. A., Huberman, M., & Moore, C. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-76-3-112-6-423 · Cited by 787

Flagged first, then by citations

Show all 29 references

Research works printed but not linked: 2

Kearon C, 2002, Blood, 100, 150a
Eriksson H, 2002, Blood, 100, 81a

Sorted by citations

Items 501–600 of 807

Direct Thrombin Inhibitors for the Treatment of Venous Thromboembolism: Analysis of the Dabigatran versus Warfarin Clinical Trial
Liem, T. K., & DeLoughery, T. G. (2011) · Seminars in Vascular Surgery · doi:10.1053/j.semvascsurg.2011.11.003 · Cited by 4
Strengths and Limitations of Standards of Care to Guide the Orthopedic Surgeon in VTE Prevention
Friedman, R. J., & Haas, S. K. (2011) · Orthopedics · doi:10.3928/01477447-20101221-25 · Cited by 4
Thirty-day mortality rate in women with cancer and venous thromboembolism. Findings from the Registro Informatizado de la Enfermedad Trombo Embólica Registry
Trujillo‐Santos, J., & Monréal, M. (2012) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e32835463a4 · Cited by 4
Thromboses veineuses cérébrales
Naggara, O. N., Guarnieri, G., Hodel, J., Piana, G., Méary, E., Charbonneau, F., Rodrigo, S., Trystram, D., Godon-Hardy, S., Oppenheim, C., et al. (2007) · EMC - Radiologie et imagerie médicale - Musculosquelettique - Neurologique - Maxillofaciale · doi:10.1016/s1879-8551(07)70792-3 · Cited by 4
Initial and Long-Term Treatment of Pulmonary Embolism: Current Approach and Future Perspectives
Ageno, W., & Donadini, M. P. (2018) · Hämostaseologie · doi:10.1055/s-0038-1641605 · Cited by 4
Guías de práctica clínica sobre diagnóstico y manejo del tromboembolismo pulmonar agudo
(ESC), G. D. T. P. E. D. Y. M. D. T. P. A. D. L. S. E. D. C. (2008) · Revista Española de Cardiología · doi:10.1016/s0300-8932(08)75741-5 · Cited by 4
Do Patients with a Family or Personal History of Venous Thromboembolism have an Increased Risk of Recurrence?
Florin, J., Stalder, O., Baumgartner, C., Méan, M., Rodondi, N., & Aujesky, D. (2021) · Thrombosis and Haemostasis · doi:10.1055/s-0041-1740184 · Cited by 4
Comparative effectiveness and safety of extended anticoagulant therapy among Medicare beneficiaries with venous thromboembolism
Park, H., Kang, H., Huang, P., Lo‐Ciganic, W., DeRemer, C. E., Wilson, D. L., & Dietrich, E. A. (2022) · Clinical and Translational Science · doi:10.1111/cts.13433 · Cited by 3
Venous Thromboembolic Disease
Weinberg, I., & Jaff, M. R. (2013) · Springer eBooks · doi:10.1007/978-1-4471-4528-8_37 · Cited by 4
Screening Feature Genes of Venous Thromboembolism with DNA Microarray
Zhou, T., Zhang, Y., Wu, P., Sun, Q., & Guo, Y. (2015) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12557 · Cited by 5
“Previous studies in subjects with VTE indicate that an extended course of anticoagulation will decrease the risk of recurrence (7,8).”
Background
Measures of vitamin K antagonist control reported in atrial fibrillation and venous thromboembolism studies: a systematic review
Mearns, E. S., Hawthorne, J., Song, J.-S., & Coleman, C. I. (2014) · BMJ Open · doi:10.1136/bmjopen-2014-005379 · Cited by 4
Therapie der Beinvenenthrombose und der Lungenembolie
Schellong, S. (2011) · Der Internist · doi:10.1007/s00108-011-2868-6 · Cited by 4
National Heart, Lung, and Blood Institute Programs for Deep Vein Thrombosis
Link, R. P. (2008) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.162461 · Cited by 4
Practical Challenges in the Management of Oral Anticoagulation
Kayser, S. R. (2005) · Progress in Cardiovascular Nursing · doi:10.1111/j.0889-7204.2005.04029.x · Cited by 4
Pulmonary embolism: Current treatment options
Meysman, M., & Haentjens, P. (2005) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-005-0034-y · Cited by 4
The Treatment of Deep Vein Thrombosis in the Pelvis and Leg
Hach-Wunderle, V., Düx, M., Hoffmann, A., Präve, F., Zegelman, M., & Hach, W. (2008) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2008.0025 · Cited by 4
Incomplete Financial Disclosure for Study of Funding and Outcomes in Major Cardiovascular Trials
Ridker, P. M. (2006) · JAMA · doi:10.1001/jama.295.23.2725-b · Cited by 4
Self-citation
Deep vein thrombosis
Kearon, C., Kovacs, M. J., & Julian, J. A. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66858-4 · Cited by 4
Duration of Anticoagulant Therapy after Initial Idiopathic Venous Thromboembolism
Frazee, L. A., & Chomo, D. L. (2003) · Annals of Pharmacotherapy · doi:10.1345/aph.1c486 · Cited by 4
Comment on the Phosphodiesterase 4D Replication Study by Bevan et al
Grétarsdóttir, S., Gulcher, J. R., Þorleifsson, G., Kong, A., & Stefánsson, K. (2005) · Stroke · doi:10.1161/01.str.0000176497.94458.27 · Cited by 4
Duration of anticoagulant therapy for patients with venous thromboembolism
Garcia, D. A. (2008) · Thrombosis Research · doi:10.1016/j.thromres.2008.08.019 · Cited by 4
Thrombophilia and the Risk of Recurrent Venous Thromboembolism—Reply
Couturaud, F., Meyer, G., & Mottier, D. (2015) · JAMA · doi:10.1001/jama.2015.12610 · Cited by 4
Reduced-Intensity Rivaroxaban for the Prevention of Recurrent Venous Thromboembolism
Crowther, M. A., & Cuker, A. C. (2017) · New England Journal of Medicine · doi:10.1056/nejme1701628 · Cited by 4
Durée optimale du traitement anticoagulant au décours d’une maladie veineuse thrombo-embolique
Savina, E. N., & Couturaud, F. (2011) · Journal des Maladies Vasculaires · doi:10.1016/s0398-0499(11)70005-1 · Cited by 3
Top practice-changing articles over the last two years
Kaatz, S., & Gage, B. F. (2013) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-013-0896-x · Cited by 3
Diagnose und Behandlung der Lungenembolie
Hecker, M., Mayer, K., & Bauer, P. (2017) · CME · doi:10.1007/s11298-017-5986-1 · Cited by 3
Guidelines on deep vein thrombosis of the Brazilian Society of Angiology and Vascular Surgery
Sobreira, M. L., Marques, M. A., Paschôa, A. F., Ribeiro, A. J. A., Casella, I. B., Burihan, M. C., Matielo, M. F., Soares, R. D. A., de Araújo, W. J. B., Joviliano, E. É., et al. (2024) · Jornal Vascular Brasileiro · doi:10.1590/1677-5449.202301072 · Cited by 6
“108 The efficacy and safety of rivaroxaban were tested in two separate investigations.”
Background
Programa educativo para la mejora de conocimientos y del rango terapéutico para pacientes anticoagulados autocontrolados
Romero-Arana, A., González-Rodríguez, M. J., Sánchez-Vega, P., García‐Iglesias, J. J., Gómez-Salgado, J. C., & Ruiz, A. R. (2024) · Atención Primaria · doi:10.1016/j.aprim.2024.103139 · Cited by 3
Chest Computed Tomography in the Emergency Department for Suspected Pulmonary Embolism: It's Time to Practice What We Preach
Piazza, G., & Goldhaber, S. Z. (2009) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2008.12.001 · Cited by 3
Self-citation
The American Academy of Neurology affirms the value of this guideline. Co-Sponsored by the Council on Cardiovascular Radiology and Intervention: American Heart Association/American Stroke Association Council on Stroke: Transient Ischemic Attack: A Statement for Healthcare Professionals From the Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or
Marks, M. P., Schwamm, L. H., Johnston, S. C., Katzan, I. L., Kelly‐Hayes, M., Goldstein, L. B., Gorelick, P. B., Halperin, J. L., Sacco, L., Adams, R. J., et al. (2010) · Cited by 3
: A Scientific Statement From the American Heart Association Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension Management of Massive and Submassive Pulmonary Embolism, Iliofemoral
Thistlethwaite, P. A., Vedantham, S., White, R. J., Goldhaber, S. Z., Kline, J. A., Michael, A. D., Jaff, R. D. O. M., McMurtry, M. S., Archer, S. L., & Cushman, M. (2011) · Cited by 3
Self-citation
Pharmacological management of pulmonary embolism
Gouin, B., Robert‐Ebadi, H., Righini, M., & Blondon, M. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1268122 · Cited by 3
Vitamin-K-Antagonisten
Rafflenbeul, E., & Müller‐Ehmsen, J. (2017) · Der Internist · doi:10.1007/s00108-016-0168-x · Cited by 3
The history and historical treatments of deep vein thrombosis: toward the era of new anticoagulants
Galanaud, J. ‐., Laroche, J.-P., & Righini, M. (2025) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2025.07.019 · Cited by 4
Randomised controlled trial: extended-duration dabigatran is non-inferior to warfarin and more effective than placebo for symptomatic VTE
Liem, T. K., & DeLoughery, T. G. (2013) · BMJ Evidence-Based Medicine · doi:10.1136/eb-2013-101317 · Cited by 3
“Context In patients with idiopathic deep vein thrombosis (DVT) or pulmonary embolism (PE), extending the duration of warfarin beyond the initial 3– 6 months of anticoagulation significantly reduces the risk for recurrence.(1) 2 Dabigatran is an oral direct-thrombin inhibitor that has been shown to be as effective as w…”
Background
Couma-Gen: Implications for Future Randomized Trials of Pharmacogenetic-Based Warfarin Therapy
Lesko, L. J., & Gage, B. F. (2008) · Personalized Medicine · doi:10.2217/17410541.5.2.163 · Cited by 3
“For future studies, patient total time in range (PTTR) may be a preferred end point because of its strong association with adverse events: patients with subtherapeutic INR values are at increased risk of thrombosis [13,14] and patients with high INR values are at increased risk of hemorrhage [15–17], although the risk…”
Background
Treatment strategies for acute pulmonary embolism
Blondon, M., Bounameaux, H., & Righini, M. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560902911470 · Cited by 3
Self-citation
Pulmonary Embolism
Weitz, J. I. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1604-7.00098-1 · Cited by 3
Management of heavy menstrual bleeding during direct oral anticoagulant therapy for recurrent venous thromboembolism
Giustozzi, M., Vedovati, M. C., & Agnelli, G. (2018) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000000697 · Cited by 3
Betrixaban in the Prevention of Venous Thromboembolism in Medically Ill Patients
Sylvester, K. W., & Connors, J. M. (2018) · Future Cardiology · doi:10.2217/fca-2018-0052 · Cited by 3
Extended oral anticoagulation after incident venous thromboembolism – a paradigm shift?
Albertsen, I. E., Piazza, G., Søgaard, M., Nielsen, P. B., & Larsen, T. B. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1755260 · Cited by 3
“0 is more effective than placebo in reducing recurrence risk but do not reduce recurrence risk as effectively as standard INR range 2–3 and do not lead to lower bleeding risk [23,24].”
Background
Outpatient Management of Patients following Pulmonary Embolism
Spurzem, J. R., & Geraci, S. A. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.04.008 · Cited by 3
Vitamin K Antagonists and Direct Thrombin Inhibitors: Present and Future
Pineo, G. F., & Hull, R. D. (2005) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2004.09.006 · Cited by 4
“0 in patients who have venous thromboembolism proved to be more effective than placebo treatment [46], a similar study that compared a target INR of 1.”
Background
TWO CASES OF BOWEL NECROSIS CAUSED BY PRIMARY THROMBOSIS OF THE SUPERIOR MESENTERIC VEIN
Tamura, T., Terasawa, T., Mizuno, Y., Okamoto, M., & Sato, M. (2007) · Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association) · doi:10.3919/jjsa.68.617 · Cited by 3
The Treatment of Deep Venous Thrombosis, Including the Newer Agents
Rectenwald, J. E., & Wakefield, T. W. (2005) · Disease-a-Month · doi:10.1016/j.disamonth.2005.03.004 · Cited by 3
Treatment and Long-Term Management of Venous Thromboembolism
AlBadri, A., & Spyropoulos, A. C. (2014) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2014.06.011 · Cited by 3
What is the optimum duration of anticoagulation for the management of patients with idiopathic deep venous thrombosis and pulmonary embolism?
Hyers, T. M., Shetty, H. G. M., & Campbell, I. A. (2010) · The Journal of the Royal College of Physicians of Edinburgh · doi:10.4997/jrcpe.2010.310 · Cited by 3
Diagnosis, Treatment, and Prevention of Cancer-Related Venous Thrombosis
Deitcher, S. R. (2008) · Elsevier eBooks · doi:10.1016/b978-0-443-06694-8.50050-6 · Cited by 3
Self-citation
Comparative efficacy and safety of low‐intensity warfarin therapy in preventing unprovoked recurrent venous thromboembolism: A systematic review and meta‐analysis
Jiang, R., Shi, Y., Zhang, R., Pudasain, B., Wang, L., Zhao, Q., Yuan, P., Guo, J., Zhu, C., & Liu, J. (2018) · The Clinical Respiratory Journal · doi:10.1111/crj.12795 · Cited by 4
Perioperative Care
Orr, J. W., Kelly, F. J., & Roland, P. Y. (2004) · Elsevier eBooks · doi:10.1016/b978-0-443-07142-3.50052-x · Cited by 3
Pulmonary Embolism and Deep Vein Thrombosis
Goldhaber, S. Z., & Piazza, G. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4557-0101-8.00038-2 · Cited by 3
Self-citation
Lower-extremity Veins
Kaufman, J. A. (2004) · Elsevier eBooks · doi:10.1016/b978-0-8151-4369-7.50024-x · Cited by 3
Comments on the 2014 ESC Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism
SEC Working Group for the ESC 2014 Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism, Embolism, E. R. F. T. E. 2. G. O. T. D. A. M. O. A. P., & SEC Clinical Practice Guidelines Committee (2014) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2014.11.003 · Cited by 3
Case report of a deep vein thrombosis in the femoral vein, an atypical presentation
Horsburgh, J. (2004) · Clinical Chiropractic · doi:10.1016/j.clch.2004.02.004 · Cited by 3
Durée optimale du traitement anticoagulant au décours d’un épisode de maladie veineuse thromboembolique
Couturaud, F., & Kearon, C. (2008) · Revue de Pneumologie Clinique · doi:10.1016/j.pneumo.2008.09.007 · Cited by 3
Stop taking warfarin? No way!
Brukner, P. D. (2009) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2009.tb02643.x · Cited by 3
Additional Topics and Discussion
Schuckers, M. E. (2010) · Information science and statistics · doi:10.1007/978-1-84996-202-5_8 · Cited by 3
Therapie und Sekund�rprophylaxe der ven�sen Thromboembolie mit Vitamin-K-Antagonisten
Bauersachs, R. M. (2003) · Der Internist · doi:10.1007/s00108-003-1081-7 · Cited by 3
Thrombotic complications and thromboprophylaxis in breast and gynaecological malignancies
Goyal, D., Choudhury, A., & Lip, G. Y. H. (2005) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/00001703-200502000-00004 · Cited by 3
Extended Anticoagulation Therapy for the Primary and Secondary Prevention of Venous Thromboembolism
Blanchard, E. M., & Ansell, J. (2005) · Drugs · doi:10.2165/00003495-200565030-00001 · Cited by 3
Current and emerging options in the management of venous thromboembolism.
Jaffer, A. K., Brotman, D. J., & Michota, F. A. (2005) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.72.suppl_1.s14 · Cited by 3
Therapeutic Update on the Prevention and Treatment of Venous Thromboembolism
McGuire, M., & Dobesh, P. P. (2004) · Journal of Pharmacy Practice · doi:10.1177/0897190004271779 · Cited by 3
The treatment of venous thromboembolic disorders: new challenges and opportunities.
Prandoni, P. (2003) · PubMed · Cited by 3
Duration of treatment
Akl, E. A., & Kearon, C. (2014) · doi:10.2217/fmeb2013.13.118 · Cited by 3
Monitoring and Follow-Up of Patients on Vitamin K Antagonist Oral Anticoagulant Therapy Using Artificial Intelligence: The AIto-Control Project
Romero-Arana, A., Romero-Sibajas, N., Arroyo-Bello, E., Ruiz, A. R., & Gómez-Salgado, J. C. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14207191 · Cited by 2
“The next most frequent indication for VKA treatment is the prevention of venous thromboembolic events for several months in primary cases, followed by chronic therapy in recurrent cases [11].”
The Pharmacogenetics of Vitamin K Antagonist Anticoagulation Drugs
Eby, C. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-283-4_8 · Cited by 2
“In a retrospective analysis of the participants in the PREVENT trial [43], Ferder et al.”
BackgroundSelf-citation
Dramatic response to low-dose rivaroxaban in an Asian patient with deep vein thrombosis and pulmonary embolism
Yamaguchi, J., Makino, K., Kusunose, Y., Higa, S., Takagi, T., Suzuki, K., & Lee, T. (2013) · Journal of Cardiology Cases · doi:10.1016/j.jccase.2013.05.002 · Cited by 2
“[1] Ridker PM, Goldhaber SZ, Danielson E, Rosenberg Y, Eby CS, Deitcher SR, Cushman M, Moll S, Kessler CM, Elliott CG, Paulson R, Wong T, Bauer KA, Schwartz BA, Miletich JP, et al.”
Background
Clinical Trials
Heskett, K. M. (2004) · Journal of Consumer Health on the Internet · doi:10.1300/j381v08n03_03 · Cited by 2
Treatment of Acute Venous Thromboembolism
Nair, S. N., Garza, N., George, M., & Kaatz, S. (2020) · Medical Clinics of North America · doi:10.1016/j.mcna.2020.03.004 · Cited by 2
Protocol for a modelling study to assess the clinical and cost-effectiveness of indefinite anticoagulant therapy for first unprovoked venous thromboembolism
Khan, F., Thavorn, K., Coyle, D., van Katwyk, S., Tritschler, T., Hutton, B., Gal, G. L., Rodger, M. A., & Fergusson, D. A. (2023) · BMJ Open · doi:10.1136/bmjopen-2021-053927 · Cited by 2
Comparing the post-operative complications following surgery for hip fracture of patients who were on warfarin versus patients who were on novel oral anticoagulants: a meta-analysis
Wei, Y., Chen, C., Yu, Z., & Guo, J. (2025) · Perioperative Medicine · doi:10.1186/s13741-025-00502-2 · Cited by 2
“Previously, warfarin, a vitamin-k antagonist, has been used as the most common oral anticoagulant (Ridker et al. 2003).”
Enantiomeric separation and quantitation of warfarin and its metabolites in human plasma by LC-MS/MS
Mostafa, A. (2016) · European Journal of Chemistry · doi:10.5155/eurjchem.7.3.357-362.1470 · Cited by 2
Sekundärprophylaxe der venösen Thromboembolie
Sternitzky, R., Hochauf, S., & Schellong, S. (2007) · Hämostaseologie · doi:10.1055/s-0037-1616897 · Cited by 2
“testeten VKA mit einer INR 1,5-2,0 gegen Placebo (PREVENT) (56).”
Background
The Role of Oral Direct Thrombin Inhibitors in the Treatment of Venous Thromboembolism
Busti, A. J., & Bussey, H. I. (2004) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.24.15.184s.43163 · Cited by 2
The Standard is Still the Standard or Why an INR of 2–3 is Still the Optimal Intensity for Secondary Prevention of Venous Thromboembolism
Kovacs, M. J. (2006) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-006-5577-6 · Cited by 3
Managing anticoagulant related coagulopathy
Jaffer, A. K. (2007) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-007-0107-8 · Cited by 2
Nuevas estrategias en la prevención secundaria de la recurrencia de la tromboembolia venosa
Lecumberri, R., Feliu, J., & Rocha, E. A. V. (2005) · Medicina Clínica · doi:10.1016/s0025-7753(05)72176-x · Cited by 2
Venous thromboembolism: Diagnosis, treatment and the prevention of long-term complications
Barnes, G. D., Froehlich, J. B., Kanthi, Y. M., & Wakefield, T. W. (2014) · Reviews in vascular medicine · doi:10.1016/j.rvm.2014.07.005 · Cited by 2
Thrombose veineuse : diagnostic et traitement
Delsart, D., Girard, G., Moulin, N., Rivron-Guillot, K., & Decousus, H. (2007) · EMC - Médecine d urgence · doi:10.1016/s1959-5182(07)73324-x · Cited by 2
Acute Deep Vein Thrombosis Cases in the Real World
Klein, S. J., & Vedantham, S. (2012) · Seminars in Interventional Radiology · doi:10.1055/s-0032-1302448 · Cited by 2
Current Treatment of Acute Lower Extremity Deep Venous Thrombosis
Janjigian, M. P., & Muhs, B. E. (2008) · The International Journal of Lower Extremity Wounds · doi:10.1177/1534734608314566 · Cited by 2
Tossing a coin or using common sense
Schulman, S. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12133 · Cited by 2
Tratamiento del tromboembolismo pulmonar agudo con heparina de bajo peso molecular subcutánea: Comparación con heparina no fracionada intravenosa
Martínez, J. L. A., Guillén, M. L. A., Remírez, M. S., Frías, M. T. Á., Dubois, J. G., & García, L. M. (2005) · Anales de Medicina Interna · doi:10.4321/s0212-71992005000400005 · Cited by 2
Life-threatening aortic thrombosis in a trauma patient homozygous for factor V Leiden mutation: Case report
Tsangaris, I., Tsaknis, G., Tsantes, A. Ε., Kopterides, P., & Armaganidis, A. (2011) · Thrombosis Journal · doi:10.1186/1477-9560-9-8 · Cited by 2
“According to the investigators, anticoagulation therapy should exceed a 3-month period after the first venous thromboembolic episode with conventional international normalized ratio (INR) target between 2 and 3 [5,6].”
Watchful Waiting vs Repair of Inguinal Hernia in Minimally Symptomatic Men
Fitzgibbons, R. J., Giobbie‐Hurder, A., Gibbs, J. O., Dunlop, D. D., Reda, D. J., McCarthy, M., Neumayer, L. A., Barkun, J. S. T., Hoehn, J. L., Murphy, J. T., et al. (2006) · JAMA · doi:10.1001/jama.295.3.285 · Cited by 500
Anticoagulation after venous thromboembolism
Eichinger, S. (2013) · Hämostaseologie · doi:10.5482/hamo-13-03-0015 · Cited by 3
Thrombophilie Génétique
Pernod, G., & Alhenc‐Gelas, M. (2011) · Elsevier eBooks · doi:10.1016/b978-2-294-71346-0.50015-x · Cited by 2
Appropriate level and length of postthrombotic warfarin treatment: an evaluation of recent developments
ten Cate‐Hoek, A. J., & Prins, M. H. (2004) · Current Opinion in Hematology · doi:10.1097/01.moh.0000130316.41033.e9 · Cited by 2
Guías de práctica clínica de la Sociedad Europea de Cardiología. Guías de práctica clínica sobre diagnóstico y manejo del tromboembolismo pulmonar agudo Grupo de Trabajo para el Diagnóstico y Manejo del Tromboembolismo Pulmonar Agudo de la Sociedad Europea de Cardiología (ESC)
Torbicki, A., Perrier, A., Konstantinides, S., & Bengel, F. M. (2016) · Cited by 2
Managing Extended Oral Anticoagulation After Unprovoked Venous Thromboembolism
Joseph, L., & Bartholomew, J. R. (2016) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248416652236 · Cited by 2
Extended non-vitamin K antagonist oral anticoagulation therapy for prevention of recurrent venous thromboembolism
Piovella, F., & Iosub, D. I. (2016) · Thrombosis Research · doi:10.1016/j.thromres.2016.12.001 · Cited by 2
Is it reasonable to use a lower DOACs dose in some patients with VTE? Yes
Imberti, D., & Mastroiacovo, D. (2017) · Internal and Emergency Medicine · doi:10.1007/s11739-017-1688-7 · Cited by 2
Venous Thrombosis
Ansell, J. (2006) · Elsevier eBooks · doi:10.1016/b978-0-7216-0284-4.50059-2 · Cited by 3
Pulmonary Thromboembolism
Morris, T. A., & Fedullo, P. F. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-3383-5.00057-9 · Cited by 2
How do contraindications to non-opioid analgesics and opioids affect the likelihood that patients with back pain diagnoses in the primary care setting receive an opioid prescription? An observational cross-sectional study
Keller, M. S., Truong, L., Mays, A. M., Needleman, J., Heilemann, M. V., & Nuckols, T. K. (2021) · BMC Family Practice · doi:10.1186/s12875-021-01386-z · Cited by 2
The expert
Cahill, M. R. (2003) · BMJ · doi:10.1136/bmj.327.7423.1089 · Cited by 2
The Indications of Temporary Inferior Vena Cava Filter for Deep Vein Thrombosis and Pulmonary Embolism
Jibiki, M., Inoue, Y., Kudo, T., Sugano, N., Inagaki, H., Isobe, M., & Kishino, M. (2011) · The Japanese Journal of Phlebology · doi:10.7134/phlebol.22-1-17 · Cited by 2
Head-to-head ex vivo comparison of clinically used direct anticoagulant drugs
Fadraersada, J., Alva-Gallegos, R., Skořepa, P., Musil, F., Javorská, L., Matoušová, K., Krčmová, L. K., Paclíková, M., Carazo, A., Blaha, V., et al. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02891-x · Cited by 2
“Heparins, both unfractionated (UFH) and low molecular weight (LMWH), as well as vitamin K antagonists (VKAs) such as warfarin are conventional anticoagulants that have been used to prevent and treat VTE in clinic for a long time.”
Influential
Treatment of Venous Thromboembolism and Long-Term Prevention of Recurrence
Eriksson, H. (2004) · Drugs · doi:10.2165/00003495-200464001-00006 · Cited by 2
“The hazard ratio for recurrence with ximelagatran was 0.16, which is lower than the hazard ratio of 0.36 that was reported with long-term low-intensity warfarin in the placebocontrolled PREVENT trial.”
BackgroundResultInfluential
Pulmonary Complications of Hematologic Diseases
Machado, R. F., & Gladwin, M. T. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-3383-5.00094-4 · Cited by 2

Authors: Ridker, P. M., Goldhaber, S. Z., Danielson, E., Rosenberg, Y., Eby, C. S., Deitcher, S. R., Cushman, M., Moll, S., Kessler, C. M., Elliott, C. G., Paulson, R., Wong, T., Bauer, K. A., Schwartz, B. A., Miletich, J. P., Bounameaux, H., & Glynn, R. J.
Affiliations: Brigham and Women's Hospital (US)
National Institutes of Health (US)
Washington University in St. Louis (US)
Cleveland Clinic (US)
University of Vermont (US)
University of North Carolina at Chapel Hill (US)
Georgetown University Medical Center (US)
LDS Hospital (US)
Altru Health System (US)
St. Boniface Hospital (CA)
Beth Israel Deaconess Medical Center (US)
University Hospital of Geneva (CH)
ORCID: Ridker, Paul M
Goldhaber, Samuel Z.
Rosenberg, Yves
Cushman, Mary
Moll, Stephan
Kessler, Craig M.
Elliott, C. Gregory
Bauer, Kenneth A.
Bounameaux, Henri
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2003-04-10
Volume: 348
Issue: 15
Pages: 1425-1434
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa035029
OpenAlex: W2112757583
Cited by: 808
References: 29
Citations by year: 2026: 3 · 2025: 9 · 2024: 5 · 2023: 7 · 2022: 10 · 2021: 13 · 2020: 16 · 2019: 23 · 2018: 16 · 2017: 19 · 2016: 25 · 2015: 24 · 2014: 45 · 2013: 38 · 2012: 44
FWCI: 53.42
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
Keywords: recurrent venous thromboembolism, long-term anticoagulation, idiopathic venous thromboembolism, major bleeding, inherited thrombophilia, international normalized ratio, benefit-risk balance
MeSH terms: Aged, Anticoagulants, Double-Blind Method, Drug Administration Schedule, Female, Hemorrhage, Humans, Male, Middle Aged, Pulmonary Embolism, Risk, Thromboembolism, Warfarin, International Normalized Ratio, Venous Thrombosis, Stroke, Secondary Prevention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks